このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage .

2026年6月16日 更新者:L'Oreal

Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage

Main objective : To evaluate the anti-aging effectiveness of the LED mask alone on at least one studied anti-aging parameters (including some targeted wrinkles) after 3 months versus baseline

Secondary objectives:

  • Anti-aging clinical score (radiance, skin tone, fine line, ptose, plumpness, ..)
  • Evaluate the consumer perception (self-evaluation)
  • Tolerance
  • Standardized pictures (all light) and pictures analysis
  • Comparison of effectiveness between the 2 groups (with and without formula

調査の概要

詳細な説明

Rational Photodamaged/aged facial skin is characterized by thinner and drier skin, with increasing sags and wrinkles due to the loss of collagen and elastic tissue. Aging skin is also much more susceptible to the development of brown spots and pigmentation.

The use of LED masks to combat skin aging is based on a scientific principle called photobiomodulation. Red and near-infrared light stimulates cellular repair mechanisms without heating or damaging tissues. Its safety profile is well-documented across all skin types and side effects of phototherapy have been shown as being minimal and temporary.

Design:

Prospective, monocentric, open, non-randomized study conducted in healthy female participant aged 35 to 60 years.

The clinical investigation is design to evaluate the efficacy and tolerability of a LED mask with or without a serum formula on the anti-aging signs of the face.

There are 2 different groups:

Group 1: investigational device alone /Group 2: investigational device + cosmetic serum. Inclusion in each group will not be randomized but will be sequential: group 1 first and then group 2.

the evaluation times are : baseline, Timmedialy, after 7 days (D7), after one month (T1M), after 2 months (T2M), after 3 months (3M) Reglementation The clinical investigation will be conducted in compliance with Good Clinical Practice (GCP) guidelines and applicable regulatory requierement for medical device investigation, ISO 14155 Statistic Safety analyses will be performed on the SS population, while efficacy analyses will be primary performed on the ITT population. If the sample size between the PP and ITT differs by more than 10%, the efficacy analysis will also be performed on the PP population.

Evaluations criterias Clinical Grading of Efficacy Parameters Assessed with scale 10 grade -point scale (0-9) or atlas photonumeric for the items : Fine lines, Roughness , Skin tone evenness, Radiance , Plumpness, Firmness, Suppleness, Elasticity, Forehead wrinkles, Glabella wrinkles, Crow's feet wrinkles, Wrinkles on the corner of lips, Ptosis on the lower face , Nasolabial fold.

The significant change versus baseline for each item will be evaluated at each time point.

The self assessment efficacy questionnaire:

The answers to the efficacy questionnaire will be summarized in the frequency table by category , together with 100% stacked bar charts.

Safety Assessment AEs will be listed by participant including time of onset, time from the first administration of clinical investigation drug, duration, intensity, action taken, corrective therapies, outcomes, relationship to clinical investigation drug and serousness.

Th dermatologist will assess the overall tolerance on a 4-grade (Very good (1); Good (2); Moderate (3); Bad (4)) at each visits.

研究の種類

介入

入学 (推定)

130

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • New Jersey
      • Piscataway、New Jersey、アメリカ、08854
        • Eurofins CRL

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  1. Female subjects aged between 35-60y.o
  2. Presenting all skin types
  3. Presenting all phototype according to Fitzpatrick Classification
  4. Sensitive skin (50%) - declarative
  5. Daily user of SPF30 or 50+ for at least 30 days
  6. User or not of LED masks (collected data)
  7. Mask adapted to the shape of the face
  8. Having mild to moderate scores (as indicated) for the items parameters
  9. Subjects willing not to change their face/eyes make-up removal products and habits, and shower habits (e.g. shampoo, shower gel), and make-up products (eyes and mouth) throughout the course of the study.
  10. Subjects willing to use the investigational devices and/or products on the face throughout the course of the study period
  11. Subjects taking an effective oral contraception or other methods of contraception for the duration of the study
  12. Written Informed Consent Form to participate in the study
  13. illingness and ability to comply with protocol requirements

Exclusion Criteria:

  1. Subjects having allergy or sensitivity to LED Light
  2. Subjects having at risk of epilepsy
  3. subject who may have headaches
  4. Subjects having participated in the clinical study using anti-aging formula on the face within at least 3 months preceding the baseline visit
  5. Subjects having used any cosmetic products with exfoliating or astringing allegation on the face within at least 4 weeks preceding the baseline visit
  6. Subject with arterial circulatory disorders in the treated area,
  7. Subjects with sensitivity troubles and pain perception impairment, facial paralysis,
  8. Subjects with degenerative and vascular retinal disease,
  9. Subjects with known problems of scarring or wound healing,
  10. History of photosensitivity or photo allergy
  11. History of chronic viral infections (herpes simplex, ZONA…) and last outbreak within 12 months preceding the baseline visit
  12. Subject having an underlying dermatological disease or conditions on the face, which in the investigator's opinion, could interfere with study evaluation
  13. Subjects with a melanoma history in the family (parents or grandparents)
  14. Subjects undergone the radiotherapy in the treated areas,
  15. Subject having excessive moles, excessive pigmented spots, tattoos, scars, irritated skin, etc. at the test area that could influence the investigation
  16. Subject with a history of surgery to the treatment concerned areas within 6 months preceding the baseline visit
  17. Subject reports (or plans to) sunbath or overexpose to UV-light (mountains sports, phototherapy, tanning salon use…) for aesthetic or therapeutic reason one month before the study start (or during the study).
  18. Subject having modified their cosmetic habits (moisturizing skin care, cleansers, make-up removers, make-up, shower products, shampoo…) during the 2 weeks before baseline visit.
  19. Subject uses or has used any of the medications or topical treatments/skincare products/procedure below without relevant wash-out period before the baseline visit (or is unwilling or unable to accept to follow the wash-out period below during the study)

    -

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:ARM 1 : MASK LED ALONE
Participant aged between 40 and 55 years who presents signs of photodamage on the face as well as anti-aging signs (wrinkles, complexion, luminosity)
Application of mask LED on the face, 5 times a week for 10 minutes for 3 months. The participant will apply his usual moisturizer and sunscreen
アクティブコンパレータ:ARM2 : DEVICE + COSMETIC FORMULA
Participant aged between 40 and 55 years who presents signs of photodamage on the face as well as anti-aging signs (wrinkles, complexion, luminosity)
application of the LED mask 5 times a week during 10 minutes and the cosmetic formula twice a day for 3 months Paticipant will apply his usual moisturizer and sunscreen

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Improvement of anti-aging parameters
時間枠:baseline to 3 months
The expert clinical grading will perform a standartied clinical evaluation oth the 14 anti-aging items with the scale 10 grade -point scale (0-9) or L'Oréal Skin Aging Atlas (scale photonumeric)
baseline to 3 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Global tolerance
時間枠:Immediate time to 3 months
The investigator will assign an overall tolerance score at each visit using the following scale 1: very good ; 2: good ; 3: Moderate ; 4 : Bad
Immediate time to 3 months
Self assessment questionnaire
時間枠:immediat time to 3 months
Participant will complete a subjective evaluation questionnaire to capture their perception of treatment outcomes. The questionnaire, using a 5 point scale (1= Disagree to 5= Agree), will include items on visible results (confort, ease of use, improvement in overall skin appereance, satisfaction)
immediat time to 3 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月1日

一次修了 (推定)

2027年4月1日

研究の完了 (推定)

2027年4月1日

試験登録日

最初に提出

2026年6月16日

QC基準を満たした最初の提出物

2026年6月16日

最初の投稿 (実際)

2026年6月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月22日

QC基準を満たした最後の更新が送信されました

2026年6月16日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • EV 2512-1248 MASK LED

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Data confidentiality, not provided for in the consent to participation, application of the GDPR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する